I. Why “Anti-VEGF + Anti-Inflammation” Dual-Target Research Is Gaining Momentum Again

In the field of neovascular age-related macular degeneration (nAMD), anti-VEGF-based strategies have reshaped vision science over the past decade. However, recent translational studies repeatedly highlight a critical limitation: not all cases respond equally to single-target anti-VEGF interventions.

Approximately one-third of study cohorts still show significant risk of long-term visual impairment. In addition, some in vivo studies have reported adverse effects such as retinal vasculitis, intraocular inflammation, and geographic atrophy.

These findings have led to renewed interest in dual-target strategies—not only suppressing VEGF-driven angiogenesis but also modulating complement activation and inflammatory pathways.

According to a study presented at ASGCT 2025, researchers developed a novel AAV2 capsid variant (AAV2.NG) using directed evolution and rational design in non-human primates (NHP). This variant demonstrated enhanced transduction efficiency in the central retina following intravitreal delivery.

The transgene payload encoded multiple functional components, including anti-VEGF scFv, aflibercept-like molecules, anti-TNFα scFv, and C3 inhibitory peptides (C3IP). Functional secretion of biologically active proteins was validated in HEK293 and ARPE19 cells, with multi-pathway inhibition confirmed in HUVEC proliferation assays, HEK-Blue TNF-α reporter systems, and Raji complement inhibition assays.

This represents a typical workflow of vector optimization + multi-payload engineering, where high-quality recombinant proteins are essential for in vitro functional validation—highlighting a core application scenario for Biofargo VEGF and growth factor RUO products.

II. VEGF Pathway Research Focus: VEGF165 and VEGF121 Are Both Critical

Within the VEGF family, VEGF-A is the most extensively studied subtype. Its major splice isoforms, VEGF165 and VEGF121, differ in subtle but functionally important ways.

2.1 VEGF165

VEGF165 contains a heparin-binding domain (HBD), allowing it to exist in both soluble form and bound to extracellular matrix or cell surface heparan sulfate proteoglycans. This enables the formation of localized concentration gradients, which are critical for in vitro modeling of angiogenic sprouting and 3D vascular network formation.

2.2 VEGF121

VEGF121 lacks the HBD and is therefore highly diffusible. It is commonly used to model long-range soluble VEGF signaling and to simulate the spatial distribution of VEGF activity in plasma-like environments.

In models such as RPE-choroid co-culture systems, HUVEC tube formation assays, and retinal organoids, researchers often switch between VEGF165 and VEGF121 depending on the required signal geometry.

For engineered anti-VEGF inhibitors (e.g., scFv, aflibercept-like constructs, bispecific proteins), both isoforms are required as reference targets to ensure consistent inhibitory activity across different spatial VEGF contexts.

Additionally, in ErbB signaling studies, NRG1-β1 acts as a key ligand for ErbB2/ErbB3 receptors and intersects with VEGF signaling in vascular homeostasis and tissue repair. It is frequently used as a complementary tool protein in cardiovascular and tumor microenvironment research.

II.5 Beyond VEGF: Why Dual-Payload Research Frameworks Are Increasingly Popular

Next-generation gene therapy research is moving beyond single-target designs. Studies in nAMD, diabetic retinopathy, and retinal vein occlusion are increasingly exploring anti-angiogenesis + anti-inflammation dual-modality strategies.

This approach is based on the understanding that while VEGF is a central regulator of angiogenesis, inflammatory mediators such as TNF-α, IL-1β, and complement C3 are critical drivers of chronic disease progression.

When combining anti-VEGF and anti-inflammatory payloads within AAV systems, researchers must validate two independent functional curves in vitro, placing higher demands on the quality of reference proteins.

If VEGF standard activity fluctuates by ±30%, EC50 measurements of anti-VEGF inhibitors may be obscured by background variability. Therefore, batch consistency and activity stability of VEGF165 and VEGF121 directly impact research efficiency and data reliability.

III. Key Technical Parameters for Recombinant VEGF / Growth Factors

Using research proteins as simple consumables can lead to significant variability in functional assays. Key parameters include:

- Purity
SDS-PAGE and SEC-HPLC dual validation with ≥95% purity. Lower purity may introduce aggregates or truncated forms, affecting EC50 reproducibility.

- Bioactivity / EC50
For VEGF165, typical ED50 in HUVEC proliferation assays is 1–10 ng/mL. VEGF121 shows comparable sensitivity in endothelial migration assays. NRG1-β1 typically shows ED50 of 1–8 ng/mL in ErbB-expressing cell lines such as MCF-7.

- Endotoxin
≤0.5 EU/mg is standard for cytokine products, especially important for primary cells and iPSC-derived endothelial cells.

- Lot-to-Lot Consistency
Critical for reproducibility. Retaining previous batches as references or purchasing sufficient quantities from a single lot is recommended.

- Animal-Free Expression Systems
E. coli or HEK293 systems are both used; selection should match downstream experimental models.

IV. Biofargo Product Portfolio

V. Laboratory Recommendations (RUO Only)

- Reconstitution
Use sterile DI water or PBS with 0.1% BSA to reduce adsorption loss.

- Storage
Store at -80°C in aliquots; avoid repeated freeze-thaw cycles.

- Working Concentration
VEGF165/121: 10 ng/mL; NRG1-β1: 1–10 ng/mL.

- Common Pitfalls
VEGF165 may appear inactive in low-BSA buffers due to adsorption loss.

VI. Conclusion + CTA

Advances in AAV engineering, dual-payload design, and complement biology are expanding the boundaries of VEGF pathway research. The quality of recombinant VEGF directly determines the reliability of in vitro validation workflows.

- View VEGF165

- View VEGF121

- View NRG1-β1

VII. Frequently Asked Research Questions

Q1: Can VEGF165 and VEGF121 be used interchangeably?

A: Not recommended. VEGF165 forms gradients; VEGF121 is diffusible.

Q2: Which VEGF isoform should be used for anti-VEGF validation?

A: Use both VEGF165 and VEGF121 in parallel.

Q3: What role does NRG1-β1 play in retinal research?

A: It serves as a complementary ErbB signaling ligand.